Table 3.

Psychosis-related general psychopathology.

Study Participant	Drug	Somatic Concern	Anxiety	Guilt Feelings	Tension	Mannerism and Posturing	Depression	Motor Retardation	Uncooperative	Unusual Thought Content	Disorientation	Poor Attention	Lack of Judgment & Insight	Disturbance of Volition	Poor Impulse Control	Preoccupation	Active Social Avoidance
male 1	Δ9-THC	✓minimal	✕	✕	✕	✓minimal	↓	✕	✕	✕	✓minimal	✓mild	✕	✕	✓minimal	✓mild	✕
male 2	Δ9-THC	✕	✕	✕	✕	✓minimal	✕	✓mild	✕	✕	✓mild	✓mild	✕	✓mild	✕	✓mild	✓mild
male 3	Δ9-THC	✓mild	✕	✓ mild	✕	✕	✓minimal	✕	✕	✓mild	✓mild	✓moderate	✕	✓moderate	✓mild	✓mild	✓minimal
male 4	Δ9-THC	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✓minimal	✕	✕
male 5	Δ9-THC	✓mild	✓mild	✕	✓mild	✕	✓mild	✕	✕	✕	✓mild	✓moderate	✕	✓mild	✓mild	✓mild	✕
male 6	Δ9-THC	✕	✕	✕	✕	✓moderate	✕	✕	✕	✓mild	✓minimal	✓mild	✓mild	✓mild	✓mild	✕	✕
male 7	Δ9-THC	✓mild	✓minimal	✕	✓minimal	✕	✕	✓mild	✓minimal	✓minimal	✓mild	✓moderate	✓mild	✓moderate	✕	✕	✕
female 1	Δ9-THC	✕	✕	✓ minimal	✓minimal	✕	✓minimal	✓mild	✓mild	✓minimal	✓minimal	✓mild	✕	✓mild	✓mild	✕	✓minimal
female 2	Δ9-THC	✕	✕	✕	✕	✕	✕	✓minimal	✕	✕	✕	✕	✕	✕	✓minimal	✕	✕
female 3	Δ9-THC	✓mild	✕	✕	✓mild	✕	✕	✕	✕	✕	✕	✓mild	✕	✓mild	✕	✓mild	✕
female 4	Δ9-THC	✕	✕	✕	✕	✓minimal	✕	✓mild	✓minimal	✓mild	✓mild	✓moderate	✓mild	✓mild	✓mild	✕	✓minimal
female 5	Δ9-THC	✓mild	✓moderate	✕	✓mild	✓minimal	✓minimal	✕	✕	✓mild	✓mild	✓mild	✕	✓mild	✕	✓moderate	✕
female 6	Δ9-THC	✕	✕	✕	✕	✓mild	✓mild	✓moderate	✕	✕	✓mild	✓moderate	✓minimal	✓mild	✕	✕	✓mild
female 7	Δ9-THC	✓mild	✓mild	✕	✓mild	✕	✕	✓mild	✕	✕	✕	✓mild	✕	✓mild	✓minimal	✓minimal	✓mild
female 8	Δ9-THC	✓mild	✓mild	✕	✓mild	✓mild	✕	✓mod./severe	✓minimal	✓moderate	✓mild	✓moderate	✓moderate	✓moderate	✕	✓mod./severe	✓mild
female 9	Δ9-THC	✕	✕	✕	✕	✓minimal	✕	✕	✓mild	✓mild	✕	✓moderate	✓mild	✕	✓minimal	✕	✕
male 1	placebo	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕
male 2	placebo	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕
male 3	placebo	✕	✓minimal	✕	✕	✕	✕	✕	✕	✕	✓minimal	✕	✕	✕	✕	✕	✕
male 4	placebo	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕
male 5	placebo	✕	✕	✕	✕	✕	✕	✕	✕	✕	✓mild	✓mild	✕	✕	✓mild	✕	✕
male 6	placebo	✕	✓minimal	✕	✓minimal	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕
male 7	placebo	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✓mild	✕	✓mild	✕	✕	✕
female 1	placebo	✓mild	✓minimal	✕	✓mild	✓minimal	✕	✕	✕	✕	✕	✕	✕	✕	✕	✓mild	✕
female 2	placebo	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕
female 3	placebo	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✓minimal	✕	✕	✕	✕	✕
female 4	placebo	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕
female 5	placebo	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕
female 6	placebo	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕
female 7	placebo	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕
female 8	placebo	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕
female 9	placebo	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕	✕

Δ9-THC, (−)-trans-Δ9-tetrahydrocannabinol; symptoms highlighted in bold were still observable 2.5 h after the injection.